Previous 10 | Next 10 |
Introduction - good things may be happening here I stopped trading or commenting on Alexion ( ALXN ) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market ( SPY ) and a major...
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer Canada NewsWire WALTHAM, Mass., Feb. 12, 2019 Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep...
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DICK'S Sporting Goods, Inc. (NYSE:DKS), Zix Corporation (NASDAQ:ZIXI), Q2...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company”), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to pur...
— Clinical Proof-of-Concept Data Expected in Second Half of 2019 — Dicerna Pharmaceuticals, Inc . (NASDAQ: DRNA), (the “Company”) a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in its Ph...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) announces several changes to its board of directors (BOD), including the elevation of J. Kevin Buchi to Chairman of the board; the appointment of Marc Kozin, professional board member, and Anna Protopapas, president and CEO of Mersana Therapeuti...
— J. Kevin Buchi Assumes Chairmanship Role and Industry Experts Marc Kozin and Anna Protopapas Join Dicerna Board — — Company Thanks Departing Chairman David Madden and Director Brian Halak — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading de...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in three investor conferences in November. ...
Dicerna Pharmaceuticals, Inc. (DRNA) Q3 2018 Results Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Paula Schwartz - Investor Relations Douglas Fambrough - President and CEO Jack Green - CFO Ralf Rosskamp - Chief Medical Officer Analysts Stephen Willey...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...